Learning Impairment and Allergic Rhinitis

Fe, Simons

doi:10.2500/108854196778996895

Cited by 147 publications

(83 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Allergic rhinitis is also considered as a risk factor for the development of asthma. Moreover, it significantly reduces quality of life, interferes with both attendance and performance at school and work, and results in a significant economic burden (Simons 1996;Blaiss 2004;Laforest et al 2005;Vandenplas et al 2008). Prevalence of allergic rhinitis is as high as 30% among adults and 40% among children.…”

Section: Tohoku University Medical Pressmentioning

confidence: 99%

Cardiac Autonomic Imbalance in Children with Allergic Rhinitis

Tascilar

Yokuşoğlu

Dündaröz

et al. 2009

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Section: Tohoku University Medical Pressmentioning

confidence: 99%

Cardiac Autonomic Imbalance in Children with Allergic Rhinitis

Tascilar

Yokuşoğlu

Dündaröz

et al. 2009

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…5 Furthermore, if left untreated, allergic rhinitis can potentially exacerbate and contribute to asthma 6 as well as other comorbidities such as conjunctivitis, otitis, dental malocclusions, sinusitis, respiratory infections, and learning problems. [7][8][9][10][11][12] Antihistamines have been a valuable allergic rhinitis treatment for decades, and data from studies in adult populations have been widely reported. Although some studies have assessed symptom relief of SAR in children using antihistamines, [13][14][15][16][17][18] including a postmarketing surveillance program, 19 only one study 13 has used the same end points as assessed in adult clinical studies.…”

mentioning

confidence: 99%

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Wahn¹,

Meltzer²,

Finn³

et al. 2003

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Background: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H 1 -antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallelgroup, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. Methods: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (±1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point.Results: Fexofenadine was significantly superior to placebo in the primary efficacy analysis (P ≤ .0001). Individual symptom scores showed statistically significant superiority compared with placebo (P < .05), including nasal congestion in the evening reflective assessment (P < .05). There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality.

show abstract

“…[7] It is a potential risk factor for the orbital complications of acute rhinosinusitis, especially in children. [8] It is widely acknowledged that the condition can also cause irritability and impaired sleep which can affect quality of life by leading to poor performance at school or work, [9,10] absenteeism from school or work, and chronic tiredness. [11] Allergic rhinitis can also have detrimental effects on emotional and social wellbeing.…”

Section: Introductionmentioning

confidence: 99%

Treatment Outcome of Intranasal Corticosteroid with Oral Antihistamines versus Oral Antihistamines Alone In Allergic Rhinitis

Bose¹,

B²,

Misra³

2017

Ann. Int. Med. Den.Res.

View full text Add to dashboard Cite

Background: Allergic rhinitis is one of the most common diseases affecting globally. The burden of this disease is huge, causing sickness absenteeism at school and workplace, dependence on medication, and suboptimal work performance by the affected population. The objective of this study is to compare the treatment outcome when intranasal corticosteroids administered along with oral antihistamines and leukotriene receptor antagonists versus oral antihistamines and leukotriene receptor antagonists alone. Methods: This is a single blinded prospective study from

show abstract

Learning Impairment and Allergic Rhinitis

Cited by 147 publications

References 0 publications

Cardiac Autonomic Imbalance in Children with Allergic Rhinitis

Cardiac Autonomic Imbalance in Children with Allergic Rhinitis

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Treatment Outcome of Intranasal Corticosteroid with Oral Antihistamines versus Oral Antihistamines Alone In Allergic Rhinitis

Contact Info

Product

Resources

About